Munich Leukemia Laboratory Selects IBM Watson and Illumina for Research Collaboration to Advance Diagnostics and Develop Personalized Treatment Tools for Leukemia & Lymphoma

IBMMunich Leukemia Laboratory (MLL), a state-of-the-art leukemia and lymphoma diagnostic and research laboratory based in Munich, has teamed up with IBM (NYSE: IBM) and Illumina, Inc. (NASDAQ: ILMN) to help build a new cognitive technology prototype that aims to help researchers improve leukemia treatment.

The prevalence of leukemia is on the rise in Europe, with 15,000 new diagnoses each year in Germany alone.(1) MLL will use NovaSeq technology from Illumina, the global leader in next-generation sequencing technology, to sequence samples from its biobank of more than 500,000 cases. MLL researchers then plan to use Watson to help analyze the genomic data alongside other data sources. The project intends to include innovative testing processes such as automated phenotyping and genotyping including whole genome sequencing (WGS) and transcriptome sequencing (RNASeq) in 5,000 cases.

The ultimate goal is to develop a Watson-based technology prototype that can help analyze genomic and phenotypic data alongside medical literature, guidelines and study results, providing clinicians with information relevant to leukemia care. Following successful development, the tool could also be made available to other laboratories in the future.

Prof. Torsten Haferlach, co-founder and CEO of MLL, states, "We at MLL are excited to combine our data and knowledge, IBM's cognitive computing tools, and Illumina's new sequencing platform to create a new era of insights in leukemia biology that will also drive more personalized treatment strategies."

"As a company committed to improving human health, we are delighted to welcome MLL as our first European customer to adopt the NovaSeq platform," said Paula Dowdy, Senior Vice President and General Manager, Illumina, Europe, Middle East, and Africa. "MLL's strategic decision to create a future path for whole-genome sequencing to help promote better health outcomes, reflects one of Illumina’s key strategies to connect genomics to the everyday lives of those living with cancer."

MLL will utilize Illumina's BaseSpace® Informatics Suite to be able to streamline data analysis, storage, data curation and aggregation. The BaseSpace Sequence Hub Frankfurt site will help MLL manage the data as the project scales and facilitates data transfer to IBM Watson. Additional tertiary analysis with BaseSpace Cohort Analyzer and BaseSpace Correlation Engine allows MLL's genomic data to be combined with other clinical data to enhance interpretation results.

"Cognitive computing is critical to help providers unlock the insights hidden in large data pools and scale their expertise in a global market through digital services," said Bart de Witte, director of digital health, IBM. "This research collaboration is indicative of the growing global market to create and implement new cognitive approaches to data-driven challenges for health systems that are increasingly overwhelmed by data."

About MLL
The Munich Leukemia Laboratory was founded in 2005 to take diagnostic responsibility for patients with leukemia and lymphoma for both in-patient and out-patient settings. The team of 150 hematologists, researchers and technicians works to optimize and refine diagnostics, including automation of laboratory procedures and improvements according to the established norms of EN ISO 15189 as well as national and international involvement in scientific projects and research trials. MLL is committed to expanding and improving high-quality diagnostics of hematological neoplasms, at the highest scientific and technical levels.

About IBM
IBM Watson is the first commercially available cognitive computing capability representing a new era in computing. The system, delivered through the cloud, analyzes high volumes of data, understands complex questions posed in natural language, and proposes evidence-based answers. Watson continuously learns, gaining in value and knowledge over time, from previous interactions. The IBM Watson Health unit helps improve the ability of doctors, researchers and insurers to innovate by surfacing insights from the massive amount of personal health data being created and shared daily.

About Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

1. European Leukemia Network.

Most Popular Now

Augmented Reality Visor to Dramatically …

Employing new photonics technology, European scientists are developing a new Augmented Reality surgical visor in a bid to improve accuracy of interventions, showing anaesthetic and medical data while superimposing a...

Read more

Interactive Health Apps May Inspire Heal…

Just like real doctors and nurses, online health tools with good - but controlled - communication skills can promote healthier lifestyles, according to researchers. However, if their tone is conversational...

Read more

Call for Papers: EHB 2017 - IEEE Interna…

22 - 24 June 2017, Sinaia, Romania. The 6-th edition of the International Conference on e-Health and Bioengineering, EHB 2017, will take place in the city of Sinaia, Romania. This year...

Read more

UK and Italian Health Tech Firms to Help…

Data sharing ambitions set out in newly published sustainability and transformation plans (STPs) have been given a boost by a new strategic partnership between data management specialist Stalis and Italy's...

Read more

From Health Apps to Nursing Robots - A G…

25 - 27 April 2017, Berlin, Germany. Around the world the subject of e-Health is steadily gaining in importance, whether it involves electronic patient files, online video consultations or any of...

Read more

Philips Teams Up with German Startup One…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a partnership agreement with German digital health company Onelife Health to jointly develop innovative connected health...

Read more

EU eHealth Competition 2017

The eHealth Competition is an initiative that rewards the best eHealth / mHealth solutions produced by European SMEs (Small and Medium Enterprises). Its objective is to support business success of...

Read more

Philips and LabPON Plan to Create World…

Royal Philips (NYSE: PHG, AEX: PHIA) and LabPON, the first clinical laboratory to transition to 100% histopathology digital diagnosis, have announced its plans to create a digital database of massive...

Read more

Virtual Reality Cognitive Training Game …

Greek researchers demonstrated the potential of a self-administered virtual supermarket cognitive training game for remotely detecting mild cognitive impairment (MCI), without the need for an examiner, among a sample of...

Read more

Technology Boost for Health and Social C…

Health and social care organisations aiming to be fully compliant with the government’s Personalised Health and Care 2020 plan, can now access electronic health record (EHR) and healthcare integration technologies...

Read more

Agfa HealthCare's Health Management Pla…

Agfa HealthCare announces today that its health management platform, including the XERO universal image viewer, has been selected to support the joint Radiotherapy Treatment Project of the Saolta University Health...

Read more

Philips Introduces Advanced Radiology So…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has unveiled new advanced radiology solutions at the 2017 European Congress of Radiology (ECR). In response to today's...

Read more
(HEALTH IT) SPACE - Take a look at who has just Joined